---
schema_version: "secwatch.filing_event.v1"
accession: "0001725160-23-000073"
form_type: "8-K"
ticker: "ZNTL"
cik: "0001725160"
company_name: "Zentalis Pharmaceuticals, Inc."
filed_at: "2023-04-26T23:59:59+00:00"
generated_at: "2026-06-16T13:12:03.934855+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Zentalis to present positive Phase 1b data for azenosertib in ovarian cancer at ASCO; announces diagnostic partnerships

## Summary
- Positive clinical data from Phase 1b trial of azenosertib + chemo in platinum-resistant ovarian cancer to be presented at ASCO June 5, 2023.
- Cyclin E1 expression shown as predictive marker for clinical benefit from azenosertib.
- Collaborations with Foundation Medicine and Roche Diagnostics to develop companion diagnostics for azenosertib.
- Azenosertib is potentially first-in-class Wee1 inhibitor being investigated in multiple trials.

## SEC filing metadata
- accession: 0001725160-23-000073
- form_type: 8-K
- ticker: ZNTL
- cik: 0001725160
- company_name: Zentalis Pharmaceuticals, Inc.
- filed_at: 2023-04-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725160/000172516023000073/0001725160-23-000073-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725160/000172516023000073/zntl-20230426.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001725160-23-000073
- JSON: https://secwatch.observer/filing/0001725160-23-000073.json
- Plain text: https://secwatch.observer/filing/0001725160-23-000073.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.